$33M to research anesthesia drugs | A medical device innovation center | COVID-19 research

"Somewhere, something incredible is waiting to be known.”  — Carl Sagan, American astronomer 

Today’s itinerary:

• $33M to research anesthesia drugs
• Indy's Sexton Biotechnologies acquired
• New cancer immunotherapy approaches
• 22,000-square-foot innovation center for medical devices
• Dry hydrogen peroxide kills SARS-COV-2
  
• Attacking variants with microscopic molecules 
• COVID, heart inflammation, & elite athletes

August 18, 2021

PUDDLE HOPS: HEALTH TECH

Image by fernando zhiminaicela from Pixabay 

• ST. LOUIS, MO—Intravenous propofol and inhaled anesthetic drugs are the two most common general anesthesia drugs for surgical patients in the U.S. Researchers at the Washington University School of Medicine in St. Louis and the University of Michigan have gotten $33 million to compare the two drugs to determine which offers better patient recovery experiences and improved clinical outcomes.

• INDIANAPOLIS, IN—BioLife Solutions, Inc. entered into a definitive agreement to acquire all remaining outstanding shares of privately held Sexton Biotechnologies, Inc., which provides products and services to those creating cell and gene therapies. The proposed acquisition will enable BioLife Solutions to expand its cell and gene therapy tools portfolio.

• PITTSBURGH, PA—A collaboration among UPMC Hillman Cancer Center, the University of Pittsburgh School of Medicine and New Jersey-based biotechnology company Avalon GloboCare Corp. aims to develop new cancer immunotherapy approaches and streamline manufacturing processes to bring treatments to cancer patients within days instead of weeks.
  
  
• ST. PAUL, MN—Ecolab, which develops and offers services, technology and systems that specialize in water treatment, purification, cleaning and hygiene, is opening a state-of-the-art innovation center. The 22,000-square-foot advanced design center will help Ecolab partner with medical device industry customers on infection prevention and help develop new solutions for hospitals and surgery centers.

Share these stories!

PANDEMIC INNOVATION

Dry hydrogen peroxide kills SARS-CoV-2

OVERLAND PARK, KS—Synexis, a developer of a product called “dry hydrogen peroxide,” received confirmation through a peer-reviewed study that their product is effective in killing the SARS-CoV-2 virus. A study published in the American Journal of Infection Control showed dry hydrogen peroxide reduced SARS-CoV-2, the virus behind COVID-19, on surfaces by 98.7 percent after two hours of continuous treatment.

Animal molecules effective against variants

PITTSBURGH, PA—Microscopic molecules developed at the University of Pittsburgh School of Medicine that neutralize the SARS-CoV-2 virus in animals are remarkably active against mutations found in variants, including Delta, according to new research by Pitt and Case Western Reserve University scientists.

COVID, heart inflammation, & elite athletes

DURHAM, NC—COVID infection can sometimes cause heart inflammation, which in some cases can be severe. Researchers at Duke Health are looking at the prevalence of COVID-related heart inflammation among top-level athletes and establish the symptoms and clinical features to ensure they receive timely and accurate diagnoses.

Share these stories!

REACH OUT

Share stories, offer suggestions or leave a comment!